Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients

Table 1 Correlation between CD47, CD68 or CD47–CD68 expression and clinicopathological parameters in breast cancer

Clinicopathological parameters	n	CD47			CD68			CD47–CD68
Clinicopathological parameters	n	High expression (%)	χ²	P	High expression (%)	χ²	P	High expression (%)	χ²	P
Age (years)
< 50	134	64.2	0.017	0.895	67.9	3.452	0.063	48.5	0.223	0.637
> 50	83	65.1	0.017	0.895	79.5	3.452	0.063	51.8	0.223	0.637
Menopause
Before	122	63.9	0.041	0.839	67.2	3.676	0.055	45.9	1.668	0.197
After	95	65.3	0.041	0.839	78.9	3.676	0.055	54.7	1.668	0.197
TNM stage
I	13	23.1	11.249	0.004	53.8	10.844	0.004	7.7	16.769	< 0.001
II	137	65.0			67.2			46.0
III	67	71.6			86.6			65.7
Histological grade
G1	36	44.4	10.825	0.004	69.4	10.500	0.005	47.2	11.300	0.004
G2	126	64.3			62.9			42.1
G3	55	78.2			89.1			69.1
Lymph node metastasis
No	96	58.3	2.875	0.090	63.5	6.678	0.010	40.6	5.759	0.016
Yes	121	69.4	2.875	0.090	79.3	6.678	0.010	57.0	5.759	0.016
ER status
Negative	121	71.1	5.139	0.023	78.5	5.192	0.023	61.2	8.253	0.004
Positive	96	56.3	5.139	0.023	64.6	5.192	0.023	35.4	8.253	0.004
PR status
Negative	120	73.3	9.117	0.003	79.2	6.235	0.013	55.8	3.948	0.047
Positive	97	53.6	9.117	0.003	63.9	6.235	0.013	42.3	3.948	0.047
HER2 gene
Non-amplification	163	61.3	2.869	0.090	72.4	0.001	0.981	48.5	0.445	0.505
Amplification	54	74.1	2.869	0.090	72.2	0.001	0.981	53.7	0.445	0.505
Recurrence
No	130	31.4	3.957	0.047	61.5	7.651	0.006	40.8	10.507	0.001
Yes	87	72.4	3.957	0.047	79.3	7.651	0.006	63.2	10.507	0.001

ISSN: 1475-2867